Celyad Oncology Sa  (CYAD)
Other Ticker:  


Celyad Oncology Sa

CYAD's Financial Statements and Analysis

Celyad Oncology Sa reported in the forth quarter of 2022 net loss per share of $-2.03 compare to earnings per share of $0.00 in the same quarter a year ago a decrease compare to $0.00 realized in previous quarter.

forth quarter of 2022
Earnings Per Share Revenues
$ -2.03 $  0 Mill
$-2.03     Unch.    

Celyad Oncology Sa's Revenue fell by 0 % in forth quarter of 2022 (Dec 31 2022) year on year, to $0 million and declined by sequentially.

Celyad Oncology Sa is Expected to report next financial results on March 22, 2024.

More on CYAD's Income Statement

Celyad Oncology Sa's in theforth quarter of 2022 recorded net loss of $-45.847 million, an increase from net loss of $-29.693 million in IV. Quarter a year ago.

Sequentially company realized a net loss, compared to net income of $0.000 million in the previous quarter.

More on CYAD's Growth

Celyad Oncology Sa Inventories
CYAD's Cash flow In theforth quarter of 2022 company's net cash flow was $34 million, capital expenditures grew by -62.84%, to $0 millions compare to same quarter a year ago and fell by